Preliminary study by the pharmaceutical showed promising results and researchers believe that the use of mRNA will be effective as a booster dose
The vaccine of Modern original against Covid-19 or modified by variants of the new coronavirus (SARS-CoV-2) proved to be efficient as a booster dose, increasing antibody levels, even for more worrying variants such as Beta, Gamma and Delta. This is one of the main results of a clinical trial carried out by the American pharmaceutical company. Still ongoing, the research led by Darin Edwards conducted a trial with 80 people who had already been immunized at least six months before. Participants were divided into four groups of 20 people and received a booster dose of an original vaccine or a modified vaccine, such as multivariate mRNA-1273,211. The first findings of the research were published in the journal “Nature Medicine”.
The emergence of new variants of SARS-CoV-2 and the possibility of being able to overcome the immunizing capacity of vaccines has aroused the scientific interest in verifying whether booster doses and specific vaccines for each variant remain effective. From the study, it was possible to see that, immediately before the people received the booster dose, they had a lower amount of antibodies in their blood than what was detected one month after receiving the second dose of the vaccine. In addition, neutralizing antibody levels to Beta, Gamma and Delta variants were also low or undetectable.
All the booster vaccines made people show increased levels of antibodies that work against the new coronavirus. The most significant increases were seen in participants who received the original Modern (mRNA-1273) and a particular modified vaccine, MRNA-1273,211. The study authors acknowledge that the analysis is preliminary, done with a small group of people and that their results are based on treatment groups that were not randomized, but believe that the use of mRNA against the worrisome Covid-19 variants should be effective for the development of booster vaccines.
*With information from EFE.